First clinical indication
Idiopathic Pulmonary Fibrosis
There is currently no treatment that stops or reverse the scarring and other than lung transplantation no curative treatment is available leading to a low median survival of 2.5 – 3.5 years after diagnosis.
Besides the increasing incidence, IPF is still considered an Orphan Disease.
Currently available drugs focus on slowing the rate of scarring in the lungs and controlling symptoms.
Some people respond well to treatment with their symptoms remaining the same for many years. For others the symptoms get worse more quickly.
IPF is a complex disease involving multiple biological pathways with suboptimal therapeutic solutions.
This triggered the clinical community to envision a combination of drugs that target single pathways, to improve efficacy by attacking the disease from multiple angles..
Unfortunately, combinations or add-on oral drugs are likely to lead to additive side effects that decrease tolerability. Inhalation of new drugs by virtue of reduced gastro-intestinal and systemic exposure may represent the only means to enable the add-on potential without introducing unacceptable additional side effects.
©2022 INHALIS
All rights reserved.
Policy / Credits